DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Adenomatous Polyposis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Familial Adenomatous Polyposis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Familial Adenomatous Polyposis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Familial Adenomatous Polyposis: An Overview
Familial Adenomatous Polyposis (FAP) is a genetic condition. It is diagnosed when a person develops more than 100 adenomatous colon polyps. An adenomatous polyp is an area where normal cells that line the inside of a person’s colon and from a mass on the inside of the intestinal tract. On average, polyps develop in people with FAP in the mid-teens. Most people with FAP will have multiple colon polyps by age 35. If FAP is not recognized and treated, there is a very high likelihood that a person will develop colorectal cancer.
Individuals with FAP also have an increased chance of developing cancer in other organs, including the stomach, small intestine, and the pancreas and biliary tree. The risk for hepatoblastoma, a type of liver cancer, is increased in children with FAP. Desmoid tumors/desmoid fibromatosis, a locally aggressive tumor that does not spread (metastasize), and a type of brain tumor called medulloblastoma can also occur in some individuals. The risk for papillary thyroid cancer is also increased.
Not all symptoms of FAP are cancer-related. Some additional features of FAP may include: osteomas (noncancerous bony growths, usually found on the jaw), extra, missing, or unerupted teeth, congenital hypertrophy of the retinal pigment epithelium (CHRPE), which is an eye condition that is present at birth that does not affect vision, but it is a condition that an eye physician may see during an examination with a special instrument called an ophthalmoscope. Benign (noncancerous) skin changes, such as epidermoid cysts and fibromas, and adrenal masses, are also typical symptoms of FAP.
There are four subtypes of familial adenomatous polyposis, namely, Classic familial adenomatous polyposis, Attenuated familial adenomatous polyposis (AFAP), Gardner syndrome, and Turcot syndrome.
Familial Adenomatous Polyposis Market Key Facts
The Familial Adenomatous Polyposis cases in the 7MM were 60,000+ in 2020.
The Familial Adenomatous Polyposis market size in the seven major markets was found to be USD 33.8 million in 2020.
FAP has a birth incidence of about 1 per 8,300, manifests equally in both sexes and accounts for less than 1% of colorectal cancer (CRC) cases. In the EU, prevalence is estimated at 1 in 11,300 to 1 in 37,600.
As per the National Institute Of Health (NIH), the reported incidence of FAP varies from 1 in 7,000 to 1 in 22,000 individuals. Additionally, when FAP results from mutations in the APC gene, it is inherited in an autosomal dominant pattern while when FAP results from mutations in the MUTYH gene, it is inherited in an autosomal recessive pattern.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Familial Adenomatous Polyposis pipeline therapies. It also thoroughly assesses the Familial Adenomatous Polyposis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Familial Adenomatous Polyposis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Familial Adenomatous Polyposis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Familial Adenomatous Polyposis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Familial Adenomatous Polyposis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Familial Adenomatous Polyposis Epidemiology, Segmented as –
Prevalent Cases of FAP in the 7MM (2019–2032)
Diagnosed Cases of FAP in the 7MM (2019–2032)
Treatable Cases of FAP in the 7MM (2019–2032)
Familial Adenomatous Polyposis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Familial Adenomatous Polyposis market or expected to be launched during the study period. The analysis covers the Familial Adenomatous Polyposis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Familial Adenomatous Polyposis drugs based on their sale and market share.
The report also covers the Familial Adenomatous Polyposis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Familial Adenomatous Polyposis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Familial Adenomatous Polyposis Market Will Evolve and Grow by 2032 @
Familial Adenomatous Polyposis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Familial Adenomatous Polyposis. Currently, SLA Pharma is leading the therapeutics market with its Familial Adenomatous Polyposis drug candidates in the most advanced stage of clinical development.
Familial Adenomatous Polyposis Companies Actively Working in the Therapeutics Market Include
Cancer Prevention Pharmaceuticals
And Many Others
Emerging and Marketed Familial Adenomatous Polyposis Therapies Covered in the Report Include:
ALFA: SLA Pharma
eRapa: Emtora Biosciences
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Familial Adenomatous Polyposis Competitive Intelligence Analysis
4. Familial Adenomatous Polyposis Market Overview at a Glance
5. Familial Adenomatous Polyposis Disease Background and Overview
6. Familial Adenomatous Polyposis Patient Journey
7. Familial Adenomatous Polyposis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Familial Adenomatous Polyposis Treatment Algorithm, Current Treatment, and Medical Practices
9. Familial Adenomatous Polyposis Unmet Needs
10. Key Endpoints of Familial Adenomatous Polyposis Treatment
11. Familial Adenomatous Polyposis Marketed Therapies
12. Familial Adenomatous Polyposis Emerging Drugs and Latest Therapeutic Advances
13. Familial Adenomatous Polyposis Seven Major Market Analysis
14. Attribute Analysis
15. Familial Adenomatous Polyposis Market Outlook (In US, EU5, and Japan)
16. Familial Adenomatous Polyposis Companies Active in the Market
17. Familial Adenomatous Polyposis Access and Reimbursement Overview
18. KOL Views on the Familial Adenomatous Polyposis Market
19. Familial Adenomatous Polyposis Market Drivers
20. Familial Adenomatous Polyposis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Synchronous Endometrial and Ovarian Cancer (SEOC) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Synchronous Endometrial and Ovarian Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the SEOC market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States